Reducing the risk of packaging failure

Reducing the risk of packaging failure

As a result of growing concerns around the threat counterfeit medicines pose to public health, the European Commission amended Directive 2001/83/EC to include additional safety features to ensure the supply chain is traceable – these are listed under the Falsified Medicines Directive (FMD).

The FMD is due to be implemented from 09 February 2019, but in order to successfully implement the changes companies need to be aware of the requirements and start testing their effectiveness.

The new features will allow wholesale distributors and pharmacists to verify that the medicine is authentic, identify individual packs, and verify that the packaging has not been interfered with.

Once manufacturers have met the specified requirements, they need to ensure that they are durable enough to withstand the demands of the supply chain. There is a risk that the safety features might be damaged in transit – costing the manufacturers in wasted products.

Our infographic looks at  how a comprehensive testing program can help medical and pharmaceutical companies reduce the risk of packaging failure, and ensure that their products arrive in a fit-for-purpose condition.

Find out more about our medical packaging testing.

Download the infographic below:

Falsified medicines directive: reducing the risk of packaging failure

Latest Resources

See all resources